Surveillance of Drug-Resistant Tuberculosis in Spain (2001–2015)

Gutiérrez-Aroca, Juan; Ruiz, Pilar; Vaquero, Manuel; Causse, Manuel; Casal, Manuel

doi:10.1089/mdr.2017.0353

Cited by 4 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…İspanya'da 15 yıllık verilerle yapılan bir çalışmada 1,207 suşun 207'sinde (% 17.2) INH, RIF, SM ve ETM'den herhangi birine karşı direnç saptanmış, ilaçların her birine karşı toplam direnç oranları INH, RIF, SM ve ETM için sırasıyla % 5.3, % 1, % 3, % 0.2 olarak bulunmuştur (10) . Bu direnç oranları aynı yazarların önceki çalışmalarındaki direnç oranlarından daha düşük bulunmuştur.…”

Section: Discussionunclassified

Sensitivity Ratios in Mycobacterium tuberculosis Complex Isolates

Öncel¹,

Karahasan²,

İlki³

et al. 2019

Ankem Derg

View full text Add to dashboard Cite

Tüberküloz tüm dünyada ciddi bir halk sağlığı sorunu olarak halen önemini korumakta, özellikle dirençli suşlarla infekte olan hastalarda ciddi morbidite ve mortaliteye neden olmaktadır. Bu çalışmanın amacı klinik örneklerden izole edilmiş Mycobacterium tuberculosis kompleksi (MTK) suşlarının primer anti-tüberküloz ilaçları olan izoniyazid (INH), rifampisin (RIF), streptomisin (SM) ve etambutole (ETM) karşı geliştirdikleri direnç oranlarının tespit edilmesidir.

show abstract

Section: Discussionunclassified

Sensitivity Ratios in Mycobacterium tuberculosis Complex Isolates

Öncel¹,

Karahasan²,

İlki³

et al. 2019

Ankem Derg

View full text Add to dashboard Cite

show abstract

“…in Spain, but the few that exist offer much lower data than those estimated by the WHO, estimating that MDR/MDR-TB would be around 1% of new TB cases [77,78,79], or around 40-60 cases per year.…”

Section: What Is the Resistance To Anti-tuberculosis Drugs In Europe ...mentioning

confidence: 92%

“…These figures are very similar to those estimated at the global level worldwide [ 76 ], although in Spain there seems to be a clear difference between the autochthonous population with low rates of MDR/MDR-TB and patients born outside our country, with clearly higher figures [ 77 ]. Unfortunately, there are hardly any publications addressing this issue in Spain, but the few that exist offer much lower data than those estimated by the WHO, estimating that MDR/MDR-TB would be around 1% of new TB cases [ 77 , 78 , 79 ], or around 40-60 cases per year.…”

Section: What Is the Resistance To Anti-tuberculosis Drugs In Europe ...mentioning

confidence: 99%

See 1 more Smart Citation

Tuberculosis in Spain: An opinion paper

Moreno Guillén,

Rodríguez-Artalejo,

Ruiz-Galiana

et al. 2023

Rev Esp Quimioter

View full text Add to dashboard Cite

This document is the result of the deliberations of the Committee on Emerging Pathogens and COVID-19 of the Illustrious Official College of Physicians of Madrid (ICOMEM) regarding the current situation of tuberculosis, particularly in Spain. We have reviewed aspects such as the evolution of its incidence, the populations currently most exposed and the health care circuits for the care of these patients in Spain. We have also discussed latent tuberculosis, the reality of extrapulmonary disease in the XXI century and the means available in daily practice for the diagnosis of both latent and active forms. The contribution of molecular biology, which has changed the perspective of this disease, was another topic of discussion. The paper tries to put into perspective both the classical drugs and their resistance figures and the availability and indications of the new ones. In addition, the reality of direct observation in the administration of antituberculosis drugs has been discussed. All this revolution is making it possible to shorten the treatment time for tuberculosis, a subject that has also been reviewed. If everything is done well, the risk of relapse of tuberculosis is small but it exists. On the other hand, many special situations have been discussed in this paper, such as tuberculosis in pediatric age and tuberculosis as a cause for concern in surgery and intensive care. The status of the BCG vaccine and its present indications as well as the future of new vaccines to achieve the old dream of eradicating this disease have been discussed. Finally, the ethical and medicolegal implications of this disease are not a minor issue and our situation in this regard has been reviewed.

show abstract

“…In one study consisting of 26,228 patients from Germany, resistance rates were reported as 7% for streptomycin, 7% for isoniazid, and 2% for rifampicin (7). Resistance rates in Spain between 2001 and 2015 were 5.3% for isoniazid, 1% for rifampicin, 3% for streptomycin, and 0.2% for ethambutol (8). Of the 316 M. tuberculosis isolates in Kosovo, resistance to isoniazid, rifampicin, ethambutol, and streptomycin was seen in 8%, 3%, 17% and 72% of isolates, respectively (9).…”

mentioning

confidence: 99%